Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Feb;8(1):4-6.
doi: 10.21037/tcr.2018.10.22.

Is re-radiation for glioblastoma after progression associated with increased survival: to treat or not to treat?

Jose A Carrillo  1   2 , Santosh Kesari  1   2
Affiliations
Editorial

Is re-radiation for glioblastoma after progression associated with increased survival: to treat or not to treat?

Jose A Carrillo et al. Transl Cancer Res. 2019 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2018.10.22). SK serves as an unpaid editorial board member of Translational Cancer Research from Aug 2019 to Jul 2021. The other author has no conflicts of interest to declare.

Comment on

References

    1. CBTRUS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 204-2006. 2010. Available online: http://www.cbtrus.org/reports/reports.html
    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 2005;352:987-96. 10.1056/NEJMoa043330 - DOI - PubMed
    1. Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA 2017;318:2306-16. 10.1001/jama.2017.18718 - DOI - PMC - PubMed
    1. Shi W, Scannell Bryan M, Gilbert MR, et al. Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. Int J Radiat Oncol Biol Phys 2018;100:38-44. 10.1016/j.ijrobp.2017.08.038 - DOI - PMC - PubMed
    1. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013;31:4085-91. 10.1200/JCO.2013.49.6968 - DOI - PMC - PubMed